Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05891379
Other study ID # XMEC-2023-003
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date July 20, 2023
Est. completion date July 31, 2025

Study information

Verified date May 2023
Source Xuanwu Hospital, Beijing
Contact Junwei Hao, MD
Phone 01083198277
Email haojunwei@vip.163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is aimed to observe the effectiveness and safety of inebilizumab in the acute phase of neuromyelitis optica spectrum disorders.


Description:

This is a a multicentric, prospective, real word study of inebilizumab in NMOSD acute attack compared with oral immunosuppressant. A total of 50 patients will be enrolled at approximately 10 centers around China.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date July 31, 2025
Est. primary completion date July 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1. Age = 18 years with anti-AQP4-IgG seropositive NMOSD as defined by 2015 NMOSD diagnostic criteria by IPND (International Panel for NMO Diagnosis); 2. In the acute phase of NMOSD (definition of acute phase: new neurological symptoms or aggravation of existing symptoms within 30 days before screening, lasting at least 24 hours without with fever); 3. Patients who plan to receive or are receiving intravenous methylprednisolone therapy; 4. Expanded disability status scale (EDSS) score = 8 and = 2.5 during the screening period; 5. Able and willing to give written informed consent; 6. Women of childbearing potential who agree to use adequate contraception during the study. Exclusion Criteria: - 1. Lactating and pregnant females; 2. Participate in other interventional studies within 30 days before screening or within 5 half-lives of the investigational agent before enrollment; 3. Combined with severe mental disorders and other conditions and unable to cooperate with follow-up; 4. History of malignancies; 5. Received plasma exchange, immunoadsorption or intravenous immunoglobulin therapy within 1 month before screening; 6. Patients with negative hepatitis B surface antibody (HBsAg) and positive hepatitis B core antibody (HBcAb), or HBsAg-positive virus carriers, or patients with active tuberculosis or positive tuberculosis screening without appropriate treatment history; 7. Other situations that researchers think are not suitable to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Inebilizumab
Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.
oral immunosuppressant
Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Xuanwu Hospital, Beijing

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Expanded Disability Status Scale (EDSS) score from baseline Change in Expanded Disability Status Scale (EDSS) score from baseline at the last visit(EDSS : Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). 6 months
Secondary Change in Expanded Disability Status Scale (EDSS) score from baseline Change in Expanded Disability Status Scale (EDSS) score from baseline at month 1, month 3(EDSS : Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). 1 months, 3 months
Secondary Percentage of Participants With Disability Improvement Disability improvement is defined as a reduction in EDSS score of: A) >=1.0 from the baseline EDSS score when the baseline score was <=5.5 B) >= 0.5 when the baseline EDSS score > 5.5(EDSS : Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). 6 months
Secondary Change in modified Rankin score (mRS) from baseline Change in modified Rankin score (mRS) from baseline at month 1, month 3, month 6(mRS : Minimum Score 0, Maximum score 6, higher scores mean a worse outcome). 1 months, 3 months, 6 months
Secondary Time to first relapse 6 months
Secondary Number of New, and/or Enlarging T2 Hyperintense Lesions Detected by Magnetic Resonance Imaging (MRI) Number of New, and/or Enlarging T2 Hyperintense Lesions Detected by Magnetic Resonance Imaging (MRI) at the last visit 6 months
Secondary Change in Timed 25 Foot Walk Test from baseline Change in time taken to complete the timed 25 foot walk test from baseline 1 months, 3 months , 6 months
Secondary Number of NMOSD attacked related rescue treatment 6 months
Secondary Change in serum GFAP levels from baseline Change in serum GFAP levels from baseline at the last visit 6 months
Secondary Change in AQP4-ab titers from baseline Change in AQP4-ab titers from baseline at the last visit 6 months
Secondary Change in Low-contrast Visual Acuity (LCVA) from baseline Change in Low-contrast Visual Acuity (LCVA) at month 3, month 6)(The LCVA test is used to determine the number of letters that can be read on a standardized low-contrast Landolt C Broken Rings Chart held at a distance of 3 meters). 3 months, 6 months
Secondary Changes in EQ-5D-5L scores from baseline Changes in EQ-5D scores from baseline at month 1 month, month 3 , month 6(EQ-5D-5L: Minimum Score 5, Maximum score 25, lower scores mean a better quality of life). 1 month, 3 months ,6 months
Secondary Change in retinal nerve fiber layer (RNFL) loss from baseline Change in retinal nerve fiber layer (RNFL) loss measured by optical coherence tomography (OCT) from baseline at month 1, month 3,month 6. 3 months ,6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT03002038 - Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Phase 2/Phase 3
Not yet recruiting NCT04064944 - Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders Phase 2
Recruiting NCT05414487 - Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
Not yet recruiting NCT05551598 - Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 2
Recruiting NCT05403138 - Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Completed NCT01845584 - Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Phase 2
Completed NCT04660539 - A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3
Recruiting NCT05199688 - A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3
Recruiting NCT05504694 - Ofatumumab in AQP4-IgG Seropositive NMOSD Phase 1/Phase 2
Recruiting NCT05346354 - Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD Phase 2/Phase 3
Completed NCT01777412 - Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Phase 1
Recruiting NCT01623076 - The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
Completed NCT01500681 - Maintenance Plasma Exchange for Neuromyelitis Optica
Not yet recruiting NCT06374264 - Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder N/A
Recruiting NCT05909761 - Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
Completed NCT02276963 - Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Phase 1
Terminated NCT04155424 - A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Phase 2/Phase 3
Completed NCT02003144 - An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Phase 3
Completed NCT03819413 - Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital